Know whether it’s viral or bacterial, sooner, with respiratory virus and pathogen panels

Information provided by Quest Diagnostics

When a patient presents for an acute visit with influenza-like symptoms, timing for diagnosis is critical. But distinguishing between different types of infection—and making a differential diagnosis—can be challenging. Influenza, respiratory syncytial virus (RSV), other viruses, and some types of bacterial infection can all share similar symptoms.

Evidence is increasing that molecular viral panel tests are preferable to traditional virus detection methods (e.g., culture, rapid antigen detection test [RADT], direct fluorescent antibody) due to1:

  • Enhanced sensitivity and specificity
  • Rapid turnaround time (24-48 hours)
  • High positive predictive values, even during times of low viral prevalence
  • A broader range of virus detection
Free Test Summary provided by Quest DiagnosticsFree Test Summary provided by Quest Diagnostics

Molecular respiratory virus and pathogen panels can help you differentiate bacterial from viral infections and reduce unnecessary antibiotic prescribing that can lead to rising rates of antimicrobial resistance.1 The panels can also help you diagnose some infections that have been commonly missed.2

Read this information sheet to learn more about molecular respiratory virus and pathogen panels that can help clinicians rapidly identify the pathogen causing a patient’s illness, allowing therapy to be tailored; this includes adding or discontinuing antibiotic therapy as indicated. Inappropriate antibiotic therapy can contribute to antimicrobial resistance, one of the biggest public health challenges of our time.3

1. Ginocchio C, McAdam A. Current best practices for respiratory virus testing. J Clin Microbiol. 2011:49(9 Suppl);S44-S48.

2. Ramanan P, Bryson AL, Binnicker MJ, et al. Syndromic panel-based testing in clinical microbiology. Clin Microbiol Rev. 2018;31(1):e00024-17.

3. Centers for Disease Control and Prevention. Antibiotic/antimicrobial resistance (AR/AMR): biggest threats and data. November 26, 2018. https://www.cdc.gov/drugresistance/biggest_threats.html. Accessed December 13, 2018.

Disclaimer

The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.